The Liquid Biopsy Services market refers to the industry that provides non-invasive diagnostic tests using circulating biomarkers, such as circulating tumor DNA, to detect and monitor diseases. As a crucial aspect of precision medicine, the Liquid Biopsy Services market size is expected to experience significant growth, driven by its growth outlook and market forecast, ultimately contributing to the industry expansion. The scope of this market encompasses various services, including next-generation sequencing, polymerase chain reaction, and droplet digital PCR, among others. According to recent estimates, the current Liquid Biopsy Services market size is approximately $1.4 billion. The market is anticipated to grow at a CAGR of 24.3% from 2026 to 2033, driven by macro drivers such as the increasing prevalence of cancer, rising demand for non-invasive diagnostic tests, and advancements in technology.